Dynamics of chronic myeloid leukemia response to dasatinib
Dynamics of chronic myeloid leukemia response to dasatinib, nilotinib, and high-dose imatinib by Adam Olshen, Min Tang, Jorge Cortes, Mithat Gonen, Timothy Hughes, Susan Branford, Alfonso Quintás-Cardama, and Franziska Michor haematol Volume 99(11): 1701 -1709 November 3, 2014 © 2014 by Ferrata Storti Foundation
The high-dose imatinib cohort. Adam Olshen et al. Haematologica 2014; 99: 1701 -1709 © 2014 by Ferrata Storti Foundation
The nilotinib cohort. Adam Olshen et al. Haematologica 2014; 99: 1701 -1709 © 2014 by Ferrata Storti Foundation
The dasatinib cohort. Adam Olshen et al. Haematologica 2014; 99: 1701 -1709 © 2014 by Ferrata Storti Foundation
Comparison of intercepts α 0 and slopes α 1 in the statistical model for treatment groups, frontline versus second-line, as well as CML stages. Adam Olshen et al. Haematologica 2014; 99: 1701 -1709 © 2014 by Ferrata Storti Foundation
Summary statistics of slopes and turning points in all four cohorts of patients. Adam Olshen et al. Haematologica 2014; 99: 1701 -1709 © 2014 by Ferrata Storti Foundation
A mathematical framework accurately predicts the dynamics of treatment responses of cohorts of patients treated with dasatinib, nilotinib and high-dose imatinib separately. Adam Olshen et al. Haematologica 2014; 99: 1701 -1709 © 2014 by Ferrata Storti Foundation
- Slides: 7